



Mr. Pranav Patel
CEO

Exemed Pharmaceuticals
Block No. 628 (A&B), ECP Canal Road
Village: Luna, Taluka: Padra,
Vadodara-391440 Gujarat India

Ref: OGYÉI/1320-4/2020
Subject: GMP Certificate

24 November 2020

Dear Mr. Pranav Patel,


Please find attached the GMP certificate of your facility registered in EudraGMDP database.

Exemed Pharmaceuticals
Block No. 628 (A&B), ECP Canal Road
Village: Luna, Taluka: Padra, Vadodara-391440 Gujarat India

Please consider that major changes related to the GMP system are to be reported on a yearly basis.

You are also requested to report the registration and distribution of the certified Active Pharmaceutical Ingredient in the EU and any event, which affects or may affect the GMP compliance.

Yours sincerely,


Dr Ferenc Lukács
Head of Inspectorate



National Institute of Pharmacy and Nutrition

CERTIFICATE NUMBER : **OGYÉI/1320-4/2020**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Hungary confirms the following:

The manufacturer: **Exemed Pharmaceuticals**

Site address: **Block No. 628 (A&B), ECP Canal Road Luna, Vadodara, Gujarat, 391 440, India**

DUNS Number : **91-683-0251**

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2020-10-08** , it is considered that it complies with:

- The principles of GMP for active substances³ referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Manufacture of active substance. Names of substances subject to inspection :

METFORMIN HYDROCHLORIDE(en)

LEVETIRACETAM(en)

DEXTROMETHORPHAN HYDROBROMIDE(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES	
Active Substance :METFORMIN HYDROCHLORIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	General Finishing Steps
	3.5.1 Physical processing steps: Micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active Substance :LEVETIRACETAM	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	General Finishing Steps
	3.5.1 Physical processing steps: Micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active Substance :DEXTROMETHORPHAN HYDROBROMIDE	

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	General Finishing Steps
	3.5.1 Physical processing steps: Micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing

Clarifying remarks (for public users)

Due to COVID-19 pandemic, this GMP certificate has been granted based on Distant Assessment. On-site inspection will be performed as soon as the restrictions are lifted.

2020-11-24

Name and signature of the authorised person of the
Competent Authority of Hungary



Dr. Ferenc Lukacs
National Institute of Pharmacy and Nutrition
Tel :+36 1 8869300
Fax :+36 1 8869463